Founded Year
2001Stage
Series B | AliveTotal Raised
$50.8MLast Raised
$49.2M | 17 yrs agoAbout Nucleonics
Nucleonics is developing a method of RNA interference to silence disease-causing genes. Initially, the company is applying its technology to develop expressed interfering RNA (eiRNA) therapies for the treatment of chronic Hepatitis B and Hepatitis C viral infections.
Nucleonics Headquarter Location
13 Summit Square Center Suite 305
Langhorne, Pennsylvania, 19047,
United States
866-268-3471
Nucleonics Patents
Nucleonics has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/22/2004 | 5/5/2009 | Transcription factors, Molecular biology, Gene expression, Human proteins, Biotechnology | Grant |
Application Date | 4/22/2004 |
|---|---|
Grant Date | 5/5/2009 |
Title | |
Related Topics | Transcription factors, Molecular biology, Gene expression, Human proteins, Biotechnology |
Status | Grant |